Physicians are getting MORE content...but is it the right content?

RESEARCH IDENTIFIES WHAT CLINICIANS VALUE FROM PHARMA’S DIGITAL CONTENT

New research of +1,830 physicians across Europe, Brazil and Japan has revealed the need for the pharmaceutical industry to produce easy to read, ‘digestible’ content in the post-COVID era as physicians receive more digital content than ever before.?

Our research shows the direct relationship between clinician treatment choices and pharma’s ability to produce digestible digital content that can be easily shared with patients. The research looked at satisfaction with digital content provided by AstraZeneca, Roche, Sanofi, Novartis, Bayer, Pfizer, Bristol-Myers Squibb, MSD, Daiichi-Sankyo, Janssen, Gilead and Takeda.?

If digital channels are to become the pre-eminent means of communicating, pharmaceutical companies need to understand what matters most to clinicians and how they are currently performing against their competitors. Providing information that is easily digestible, keeps physicians up-to-date with scientific developments, and helps them deliver better patient care is fundamental to driving satisfaction with the digital content pharma provides.

We're?starting to see a divide between the pharma companies who are keeping pace with clinician needs in digital, and those who are beginning to fall behind. We ranked clinician satisfaction across therapy areas, across markets and between pharma companies. We've assessed how satisfied clinicians are, which companies are ahead of the curve in producing interactive content and which are lagging. What's clear is there is more the pharma industry can be doing to improve.

Bryter uses a range of approaches and methodologies incorporating qualitative techniques like digital ethnography and advanced analytical techniques for optimizing content strategy. Bryter’s Digital Campaign Builder is a choice-based tool that helps to truly optimize integrated channel and content preferences.?